


ASX Announcement

CathRx quarterly sales results for Q1 FY2010



SYDNEY Australia 9 October 2009:

Cardiac catheter manufacturer CathRx Ltd (ASX: CXD) announced today it had achieved sales of \$143,100 in Q1 of FY2010. The results were higher than total sales achieved by the Company for all of FY2009, but were lower than the sales forecast communicated earlier this year. Approximately \$20,000 (35%) of the shortfall was due to the rise in the Australian dollar during the period, while the balance of the shortfall resulted from some one-off timing delays. CathRx notes that summer vacations in Europe tend to delay new initiatives through July and August. Management expects that sales targeted for Q1 will now occur in the December quarter.

Over the past 6 months, the Company has been successful in signing distribution agreements across key European centres such as Germany, Switzerland, Austria, Spain and Portugal as well as Scandinavia, Central Eastern Europe and the Baltic States. Many of these distributors have shown their commitment by placing their first orders.

While preferring to be precisely on time with their sales rollout, management are satisfied that its sales program remains essentially on track.

End



CathRx Ltd
ABN 23 089 310 421

5 Parkview Drive
Homebush Bay NSW 2127
Australia
Telephone +61 (0)2 9397 5700
Facsimile +61 (0)2 9397 5701
www.cathrx.com

About CathRx

CathRx is a medical device company which manufactures and markets advanced cardiac catheter solutions for the treatment of people suffering from electrical problems of the heart known as cardiac arrhythmias. CathRx's proprietary diagnostic and therapeutic catheters are designed to give physicians the tools to successfully treat patients with speed, safety and precision. CathRx's diagnostic products are now being sold in Europe.

About cardiac arrhythmias

Cardiac arrhythmia describes a group of increasingly common conditions where there is abnormal electrical activity in the heart. The beating of a normal heart is controlled by electrical impulses. When these impulses are uncoordinated the heart fails to function properly. This can result in complications ranging from fatigue to stroke and even death. More than 10 million people worldwide suffer from abnormal heart rhythms. Atrial fibrillation is the most common form of arrhythmia and affects over 5 million people worldwide. Current drug therapies often fail to control the problem and can have side effects. Physicians worldwide are increasingly using cardiac catheters to diagnose and successfully treat arrhythmias.

Would you like to receive CathRx ASX releases via email?

Go to www.cathrx.com and become a subscriber to our investor communications.

For further information:

Neil Anderson
CathRx Chief Executive Officer
Ph: 02 9397 5700

Amanda Wong
CathRx Chief Financial Officer
Ph: 02 9397 5700